Lung Cancer Clinical Trial
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Summary
Primary Objectives:
To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer (mCRPC) who were naïve to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)-containing therapy, or non-small cell lung cancer (NSCLC) who progressed on anti-PD-1/PD-L1-containing therapy, and to confirm the recommended Phase 2 dose (RP2D).
To assess the response rate of isatuximab in combination with REGN2810 in participants with either mCRPC who were anti-PD-1/PD-L1 therapy naive, or NSCLC who progressed on anti-PD-1/PD-L1 therapy, or of isatuximab as single agent in participants with mCRPC.
Secondary Objectives:
To evaluate the safety of the combination of isatuximab with REGN2810 or isatuximab monotherapy.
To evaluate the immunogenicity of isatuximab and REGN2810.
To characterize the pharmacokinetic (PK) profile of isatuximab single agent or in combination with REGN2810, and to characterize the PK of REGN2810 in combination with isatuximab.
To assess overall efficacy of isatuximab in combination with REGN2810 or as a single agent.
Full Description
The total study duration per participant was up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.
Eligibility Criteria
Inclusion Criteria:
Participants must had a known diagnosis of either metastatic castration-resistant prostate cancer (mCRPC) or non-small cell lung cancer (NSCLC) with evidence of measurable disease.
Failure of, inability to, or refusal to receive standard of care.
Greater than or equal to (>=) 18 years of age.
Exclusion Criteria:
Prior exposure to isatuximab or participation in clinical studies with isatuximab.
For participants with mCRPC, prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1 pathway.
Evidence of other immune related disease /conditions.
History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
Had received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus were permitted.
Prior solid organ or hematologic transplant.
Eastern Cooperative Oncology Group performance status (PS) >=2.
Poor bone marrow reserve.
Poor organ function.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 15 Locations for this study
Birmingham Alabama, 35249, United States
Atlanta Georgia, 30322, United States
Hackensack New Jersey, 07601, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
Bordeaux Cedex , 33076, France
Villejuif , 94800, France
Rozzano Milano, 20089, Italy
Orbassano Torino, 10043, Italy
Napoli , 80131, Italy
Padova , 35128, Italy
Verona , 37134, Italy
Tainan , 704, Taiwan
Taipei 100 , , Taiwan
Sutton Surrey, SM2 5, United Kingdom
Newcastle upon Tyne , NE7 7, United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.